Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000
| Autor: | Nahum Erlich, Jamal Zidan, Lael-Anson Best, Alexander Beny, Raphael Rubinov, Nissim Haim, Shimon Meretyk, Eliahu Gez, Diana Gaitini, Abraham Kuten, Ofer Native, Avi Stein |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Injections Subcutaneous Phases of clinical research Alpha interferon Vinblastine Gastroenterology Nephrectomy Disease-Free Survival Renal cell carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Prospective Studies Survival rate Carcinoma Renal Cell Interferon alfa Aged Aged 80 and over business.industry Interferon-alpha Middle Aged medicine.disease Kidney Neoplasms Surgery Treatment Outcome Oncology Injections Intravenous Interleukin-2 Female Fluorouracil business Kidney disease medicine.drug |
| Zdroj: | Cancer. 95(8) |
| ISSN: | 0008-543X |
| Popis: | BACKGROUND The current study evaluated the efficacy and toxicity of interleukin-2 (IL-2), interferon-α (IFN-α), 5-fluorouracil (5-FU), and vinblastine (VBL) in the treatment of metastatic renal cell carcinoma (MRCC). METHODS Sixty-two MRCC patients, median age 63 years, received immunochemotherapy. Eastern Cooperative Oncology Group performance status was 1 for 45 patients and 2 for 17 patients. Fifty-four patients underwent nephrectomy prior to treatment. Sites of disease were lungs, lymph nodes, bone, kidney, and liver. Treatment consisted of IL-2 10 MIU/m2 subcutaneous (SC), three times per week, Weeks 1-4; IFN-α 6 MIU/m2 SC, once per week, Weeks 1-4 and 9 MIU/m2, three times per week, Weeks 5-7; 5-FU 600 mg/m2 and VBL 6 mg/m2, intravenous bolus, Day 1 of Weeks 5 and 7. RESULTS In a median followup of 34 months, 62 patients were evaluated for tumor response. Four patients achieved complete response for 26+, 34+, 51+, and 56+ months, respectively; 14 patients achieved partial response for a median of 14 months; and 20 patients achieved stable disease for a median of 9 months. Seven patients (5 partial response, 2 stable disease) underwent complete resection of residual tumor. Five patients remained alive with no evidence of disease for 27, 32, 36, 42, and 48 months, respectively. Nine patients achieved long-term complete response for a median of 36 months. Three-year survival rate for the entire group and for 11 complete responders was 88%. Common side effects were flu-like symptoms, nausea, headache, and depression. Four patients were excluded because of treatment intolerance, and one patient died after nephrectomy. CONCLUSIONS Immunochemotherapy is effective and well-tolerated by patients with MRCC. Surgical intervention for resection of residual disease is justified. Cancer 2002;95:1644–9. © 2002 American Cancer Society. DOI 10.1002/cncr.10842 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text